Takeda Pharmaceutical Co.’s efforts to hide the cancer risks of its Actos diabetes medicine showed a “reckless disregard” for patient safety and a drive to protect billions of dollars in sales, a lawyer told jurors in the first federal trial over the medication.
California’s limit of $250,000 on medical malpractice damages for pain and suffering, which became a model for other states almost 40 years ago, could be increased under a voter initiative to be submitted today.
Italy’s antitrust regulator fined Novartis AG and Roche Holding AG 182.5 million euros ($251 million) for allegedly colluding to prevent the use of Roche’s Avastin cancer drug as a treatment for an eye disease.
Boston Scientific Corp. won’t begin a study of its hypertension treatment until it can analyze a failed effort by Medtronic Inc. and review its approach with U.S. regulators, Chief Executive Officer Michael Mahoney said.
Teva Pharmaceutical Industries Ltd., the world’s biggest generic-drug maker, was accused by lawyers at a Nevada trial of putting profit ahead of the safety of colonoscopy patients who got the company’s Propofol anesthetic from reused vials.